The collaboration will help Hovione’s expertise and experience to overcome drug delivery challenges and the supply of GMP materials from phase I to commercial scale using Solvias state chemistry.
As part of the collaboration, Hovione will also use Solvias’ co-crystallization expertise and capabilities to overcome poor bioavailability and other drug delivery challenges.
Hovione particle design vice president Colin Minchom said, "We are delighted to announce this collaboration with Solvias increasing the breadth of drug delivery solutions through our Particle Design offering."
Solvias business development analytics global head Martina Diekmann said, ”In establishing this agreement with Hovione, we are able to generate added value for our customers and to help them solving their drug delivery requirements."